Pacific Biosciences of California Company Profile (NASDAQ:PACB)

About Pacific Biosciences of California

Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NASDAQ
  • Symbol: PACB
  • CUSIP: 69404D10
Key Metrics:
  • Previous Close: $5.12
  • 50 Day Moving Average: $4.90
  • 200 Day Moving Average: $7.01
  • 52-Week Range: $92,677,000.00 - $3.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.00
  • P/E Growth: -0.19
  • Market Cap: $474.51M
  • Outstanding Shares: 92,677,000
  • Beta: 1.97
Profitability:
  • Net Margins: -81.99%
  • Return on Equity: -75.50%
  • Return on Assets: -49.35%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 3.82%
  • Quick Ratio: 3.30%
Additional Links:
Companies Related to Pacific Biosciences of California:

Analyst Ratings

Consensus Ratings for Pacific Biosciences of California (NASDAQ:PACB) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $11.70 (128.52% upside)

Analysts' Ratings History for Pacific Biosciences of California (NASDAQ:PACB)
Show:
DateFirmActionRatingPrice TargetDetails
2/3/2017Cantor FitzgeraldReiterated RatingBuy$8.00View Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHold$12.00View Rating Details
6/27/2016CL KingInitiated CoverageBuy$11.00View Rating Details
4/15/2016MKM PartnersInitiated CoverageNeutral$16.50View Rating Details
4/14/2016First AnalysisInitiated CoverageOverweight$11.00View Rating Details
2/5/2016StephensReiterated RatingBuyView Rating Details
2/4/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$9.00 -> $11.00View Rating Details
10/23/2015William BlairReiterated RatingBuyView Rating Details
8/27/2015Maxim GroupReiterated RatingBuy$9.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Pacific Biosciences of California (NASDAQ:PACB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/19/2017        
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)ViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pacific Biosciences of California (NASDAQ:PACB)
Current Year EPS Consensus Estimate: $-0.88 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.26)($0.26)
Q2 20162($0.23)($0.22)($0.23)
Q3 20162($0.21)($0.17)($0.19)
Q4 20162($0.23)($0.21)($0.22)
Q1 20172($0.21)($0.19)($0.20)
Q2 20172($0.19)($0.18)($0.19)
Q3 20172($0.18)($0.17)($0.18)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacific Biosciences of California (NASDAQ:PACB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pacific Biosciences of California (NASDAQ:PACB)
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 69.17%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.00View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.00View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pacific Biosciences of California (NASDAQ:PACB)
DateHeadline
thestreet.com logoGlobal Blood Therapeutics Prices A $125.0 Million Upsized Common Stock Public Offering (NASDAQ:PACB)
www.thestreet.com - February 22 at 9:11 AM
News IconBrain Scans Could Identify Babies at Risk of Developing Autism (NASDAQ:PACB)
oakridgeobserver.com - February 22 at 9:11 AM
News IconAnalysts Review on Trending Stock: Pacific Biosciences of California (NASDAQ:PACB) (NASDAQ:PACB)
prensariotiretail.com - February 22 at 9:11 AM
News IconAnalysts Peer Into Their Crystal Balls For Pacific Biosciences of California, Inc. (NASDAQ:PACB): Where Is It headed? - Winfield Review (NASDAQ:PACB)
winfieldreview.com - February 21 at 5:46 PM
News IconTechnical Trading: Focus on Shares of Pacific Biosciences of California Inc (PACB) - Davidson Register (NASDAQ:PACB)
davidsonregister.com - February 21 at 5:46 PM
News IconStock Price of Pacific Biosciences of California, Inc. (PACB) Increases 6.39% - Highland Mirror (NASDAQ:PACB)
www.highlandmirror.com - February 21 at 5:46 PM
News IconPrice Target Of Pacific Biosciences of California, Inc. (NASDAQ:PACB)At $10.2 - Transcript Daily (NASDAQ:PACB)
transcriptdaily.com - February 20 at 9:37 AM
News IconPacific Biosciences of California, Inc. (NASDAQ:PACB) Projected to Achieve EPS Of $-0.22 - Stock Observer (NASDAQ:PACB)
www.thestockobserver.com - February 20 at 9:37 AM
News IconTicker Scope: Tracking Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Sherwood Daily (NASDAQ:PACB)
sherwooddaily.com - February 16 at 11:41 PM
News IconShares in Focus: Pacific Biosciences of California Inc. (PACB) - BVN (NASDAQ:PACB)
bvnewsjournal.com - February 16 at 11:41 PM
News IconShares in Focus: Pacific Biosciences of California Inc. (PACB) - BVN (NASDAQ:PACB)
bvnewsjournal.com - February 16 at 11:41 PM
finance.yahoo.com logoSMRT Sequencing to be Featured in More Than 35 Presentations at the Annual AGBT Conference (NASDAQ:PACB)
finance.yahoo.com - February 13 at 9:28 AM
News IconPacific Biosciences of California, Inc. (NASDAQ:PACB) EPS Estimate At $-0.13 - Transcript Daily (NASDAQ:PACB)
transcriptdaily.com - February 12 at 7:00 PM
News IconPacific Biosciences of California, Inc. (NASDAQ:PACB) Projected EPS At $-0.22 - Stock Observer (NASDAQ:PACB)
www.thestockobserver.com - February 12 at 7:00 PM
News IconMarket Focus: Checking Up on Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Benton Bulletin (NASDAQ:PACB)
bentonbulletin.com - February 11 at 1:05 AM
News IconPacific Biosciences of California, Inc. (NASDAQ:PACB) Target Price At $10.2 - Transcript Daily (NASDAQ:PACB)
transcriptdaily.com - February 9 at 8:29 PM
istreetwire.com logoStocks in the Spotlight: Pacific Biosciences of California, Inc. (PACB ... - iStreetWire (NASDAQ:PACB)
istreetwire.com - February 8 at 8:05 PM
capitalcube.com logoPacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 (NASDAQ:PACB)
www.capitalcube.com - February 8 at 8:04 PM
News IconCannabinoids’ Potential Boosts GW Pharmaceuticals (GWPH); UBS Eyeing Opportunity in Pacific Biosciences (PACB) (NASDAQ:PACB)
galaxystocks.com - February 7 at 8:13 PM
capitalcube.com logoPacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q4, 2016 By the Numbers : February 7, 2017 (NASDAQ:PACB)
www.capitalcube.com - February 7 at 8:13 PM
fool.com logoWhy Pacific Biosciences of California Jumped 10.5% in January (NASDAQ:PACB)
www.fool.com - February 6 at 11:40 AM
finance.yahoo.com logoPacific Biosciences (PACB) Q4 Loss Narrower than Estimated (NASDAQ:PACB)
finance.yahoo.com - February 6 at 9:15 AM
istreetwire.com logoMomentum Stocks: Abraxas Petroleum Corporation (AXAS), Pacific ... - iStreetWire (NASDAQ:PACB)
istreetwire.com - February 3 at 7:56 PM
finance.yahoo.com logoEdited Transcript of PACB earnings conference call or presentation 2-Feb-17 9:30pm GMT (NASDAQ:PACB)
finance.yahoo.com - February 3 at 7:56 PM
reuters.com logoBRIEF-Pacific Biosciences announces Q4 2016 financial results (NASDAQ:PACB)
www.reuters.com - February 2 at 8:04 PM
4-traders.com logoPacific Biosciences of California : reports 4Q loss (NASDAQ:PACB)
www.4-traders.com - February 2 at 8:04 PM
seekingalpha.com logoPacific Biosciences of California (PACB) (NASDAQ:PACB)
seekingalpha.com - February 2 at 8:04 PM
biz.yahoo.com logoQ4 2016 Pacific Biosciences of California Inc Earnings Release - After Market Close (NASDAQ:PACB)
us.rd.yahoo.com - February 2 at 8:04 PM
us.rd.yahoo.com logoPacific Biosciences Announces Fourth Quarter 2016 Financial Results (NASDAQ:PACB)
us.rd.yahoo.com - February 2 at 8:04 PM
sg.finance.yahoo.com logoPacific Biosciences reports 4Q loss (NASDAQ:PACB)
sg.finance.yahoo.com - February 2 at 8:04 PM
fool.com logoPacific Biosciences of California Reports Bigger Loss in Q4 (NASDAQ:PACB)
www.fool.com - February 2 at 8:04 PM
News IconPacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target At $11 - Transcript Daily (NASDAQ:PACB)
transcriptdaily.com - February 1 at 8:17 PM
finance.yahoo.com logoPacific Biosciences (PACB): What Awaits in Q4 Earnings? (NASDAQ:PACB)
finance.yahoo.com - January 31 at 8:05 PM
News IconWhat are Research Firms Saying About Pacific Biosciences of California, Inc. (NASDAQ:PACB)? - Aiken Advocate (NASDAQ:PACB)
aikenadvocate.com - January 31 at 12:47 AM
News IconCCI, ADX, and Williams %R Review for Pacific Biosciences of California Inc. (PACB) - Rives Journal (NASDAQ:PACB)
rivesjournal.com - January 28 at 7:14 PM
News IconStock Seesawing as Volatility Sweeps in on Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Wall Street Beacon (NASDAQ:PACB)
wsbeacon.com - January 27 at 5:27 AM
istreetwire.com logoStocks To Track: Viavi Solutions Inc. (VIAV), Pacific Biosciences of California, Inc. (PACB), ON Semiconductor ... - iStreetWire (NASDAQ:PACB)
istreetwire.com - January 27 at 5:27 AM
News IconEarnings in Full Force, Analysts Take Aim at Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Wall Street Beacon (NASDAQ:PACB)
wsbeacon.com - January 26 at 4:25 AM
istreetwire.com logoMomentum Stocks: Schlumberger Limited (SLB), Pacific Biosciences of California, Inc. (PACB), Novavax, Inc. (NVAX) - iStreetWire (NASDAQ:PACB)
istreetwire.com - January 26 at 4:25 AM
News IconBrokers Issue New Targets On Pacific Biosciences Of California, Inc. (NASDAQ:PACB) (NASDAQ:PACB)
flapship.com - January 25 at 11:24 PM
News IconPriming The Pump: Stock Volatility Spotted in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Wall Street Beacon (NASDAQ:PACB)
wsbeacon.com - January 24 at 8:51 AM
istreetwire.com logoTrader Alert: UnitedHealth Group Incorporated (UNH), Pacific Biosciences of California, Inc. (PACB), Valero Energy ... - iStreetWire (NASDAQ:PACB)
istreetwire.com - January 24 at 8:51 AM
openpr.com logoPacific Biosciences of California (NASDAQ:PACB) Investor Investigation over possible Violations of Securities Laws (NASDAQ:PACB)
www.openpr.com - January 23 at 7:27 PM
News IconCCI Level Check for Pacific Biosciences of California Inc. (PACB) - Sherwood Daily (NASDAQ:PACB)
sherwooddaily.com - January 22 at 6:53 PM
News IconPacific Biosciences of California, Inc. (NASDAQ:PACB) Projected to Achieve EPS Of $-0.23 - Stock Observer (NASDAQ:PACB)
www.thestockobserver.com - January 22 at 6:53 PM
News IconNASDAQ:PACB Shareholder Alert: Investigation over possible Securities Laws Violations by Pacific Biosciences of California (NASDAQ:PACB)
www.groundreport.com - January 21 at 6:52 PM
News IconLooking at Moving Averages for Pacific Biosciences of California Inc. (PACB) - Rives Journal (NASDAQ:PACB)
rivesjournal.com - January 21 at 12:57 AM
News IconKeeping Tabs on Technicals for Pacific Biosciences of California Inc. (PACB) - Sherwood Daily (NASDAQ:PACB)
sherwooddaily.com - January 19 at 11:45 PM
News IconAmplified Volatility Spotted in Shares of Pacific Biosciences of ... - Wall Street Beacon (NASDAQ:PACB)
wsbeacon.com - January 19 at 11:45 PM
fool.com logoDid Roche Just Hand Illumina Pacific Biosciences' Head on a Platter ... - Motley Fool (NASDAQ:PACB)
www.fool.com - January 19 at 11:45 PM

Social

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Where is Pacific Biosciences of California's stock going? Where will Pacific Biosciences of California's stock price be in 2017?

5 equities research analysts have issued 1 year target prices for Pacific Biosciences of California's shares. Their forecasts range from $8.00 to $16.50. On average, they anticipate Pacific Biosciences of California's share price to reach $11.70 in the next year.

When will Pacific Biosciences of California announce their earnings?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Wednesday, April, 19th 2017.

What are analysts saying about Pacific Biosciences of California stock?

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:

  • Cantor Fitzgerald analysts commented, "Solid 4Q16 results despite lower than-expected Sequel bookings. The company reported total revenues of $25.7M, $2.5M above our estimate of $23.2M and $2.7M above FactSet consensus of $23.0M. System revenue beat due to strong placements in the quarter, slightly offset by lower-than-expected consumable revenue." (2/3/2017)

  • According to Zacks Investment Research, "In the past six months, Pacific Biosciences’ share price persistently underperformed the broader industry trend. However, in the last 30 days, earnings estimates have been moved downwards reflecting sluggish third quarter performance. We note that, Pacific Biosciences exhibited a promising third quarter of 2016, registering narrower loss on a year-over-year basis and squarely beating the Zacks Consensus Estimate. However, the guidance cut for the full year fails to impress. Solid contribution from the Instrument and Consumable revenue platforms is a significant positive. We are also upbeat about the higher margin sales of the SequelTM System. On the flipside, persistent losses and cash burn are the primary headwinds. Moreover, the headwind related to the limited availability of SMRT cells (Single Molecule, Real-Time) for the Sequel system, flat contractual revenues in the last reported quarter and higher non-cash operating expenses will hurt the" (11/29/2016)

Who owns Pacific Biosciences of California stock?

Pacific Biosciences of California's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Arrowpoint Asset Management LLC (1.59%), State Street Corp (1.50%), Levin Capital Strategies L.P. (1.13%), Alyeska Investment Group L.P. (0.53%), Allianz Asset Management AG (0.45%) and Thrax Management LLC (0.44%). Company insiders that own Pacific Biosciences of California stock include Brian B Dow, James Michael Phillips and Kevin P Corcoran.

Who sold Pacific Biosciences of California stock? Who is selling Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, AQR Capital Management LLC and Commerzbank Aktiengesellschaft FI.

Who bought Pacific Biosciences of California stock? Who is buying Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was bought by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Arrowpoint Asset Management LLC, Alyeska Investment Group L.P., Russell Investments Group Ltd., Tudor Investment Corp Et Al, State Street Corp, Moloney Securities Asset Management LLC and Dynamic Technology Lab Private Ltd. Company insiders that have bought Pacific Biosciences of California stock in the last two years include Brian B Dow and Kevin P Corcoran.

How do I buy Pacific Biosciences of California stock?

Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pacific Biosciences of California stock cost?

One share of Pacific Biosciences of California stock can currently be purchased for approximately $5.12.

Pacific Biosciences of California (NASDAQ:PACB) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Earnings History Chart

Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Dividend History Chart

Dividend Payments by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Last Updated on 2/27/2017 by MarketBeat.com Staff